MedPath

Correlation between glucose variability evaluated by CGMS and labile hemoglobin A1c measured by high performance liquid chromatography (HPLC) in Japanese patients with diabetes.

Not Applicable
Conditions
diabetes
Registration Number
JPRN-UMIN000030696
Lead Sponsor
St. Marianna University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who fall into any of the following criteria are unable to participate in the study. 1)patients who are considered to be ineligible for the study by the attending doctor,2)sever renal dysfunction(estimated glomerular filtration rate<45mL/min/1.73m2) or nephrotic syndrome,3)high blood urea nitrogen(>50mg/dL),4)hyper splenism about hemorrhage, hemolytic anemia, liver cirrhosis, 5)iron deficient anemia or being treated with iron, 6) a history of splenectomy, 7)being treated with antiplatelet agent about aspirin, 8)being treated with supplement contain vitamin C, 9)abnormal hemoglobinemia, 10)acute metabolic disturbance(diabetic ketoacidosis, hyperosmolar hyperglycemic syndrome, lactic acidosis, hypoglycemia) or sick day.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To calculate the coefficient and 95% interval(CI) between the values of labile HbA1c measured by HPLC and standard deviation (SD) of 24-hr glucose concentration measured by CGM prior to evaluate labile HbA1c.
Secondary Outcome Measures
NameTimeMethod
To calculate the coefficient and 95% interval(CI) between the values of labile HbA1c and mean glucose level or mean amplitude of glycemic excursions(MAGE).
© Copyright 2025. All Rights Reserved by MedPath